TY - JOUR
T1 - Entecavir versus tenofovir in patients with chronic hepatitis b
T2 - Enemies or partners in the prevention of hepatocellular carcinoma
AU - Lee, Sung Won
AU - Choi, Jonggi
AU - Kim, Seung Up
AU - Lim, Young Suk
N1 - Publisher Copyright:
© 2021 by Korean Association for the Study of the Liver.
PY - 2021/7
Y1 - 2021/7
N2 - Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
AB - Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
UR - http://www.scopus.com/inward/record.url?scp=85110089866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110089866&partnerID=8YFLogxK
U2 - 10.3350/cmh.2021.0179
DO - 10.3350/cmh.2021.0179
M3 - Article
C2 - 34157830
AN - SCOPUS:85110089866
SN - 2287-2728
VL - 27
JO - Clinical and molecular hepatology
JF - Clinical and molecular hepatology
IS - 3
ER -
